DK2528602T4 - Formuleringer af bendamustin - Google Patents

Formuleringer af bendamustin Download PDF

Info

Publication number
DK2528602T4
DK2528602T4 DK11737745.7T DK11737745T DK2528602T4 DK 2528602 T4 DK2528602 T4 DK 2528602T4 DK 11737745 T DK11737745 T DK 11737745T DK 2528602 T4 DK2528602 T4 DK 2528602T4
Authority
DK
Denmark
Prior art keywords
bendamustin
formulations
Prior art date
Application number
DK11737745.7T
Other languages
English (en)
Other versions
DK2528602T3 (da
Inventor
Nagesh R Palepu
Philip Christopher Buxton
Original Assignee
Eagle Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44309429&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK2528602(T4) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Eagle Pharmaceuticals Inc filed Critical Eagle Pharmaceuticals Inc
Publication of DK2528602T3 publication Critical patent/DK2528602T3/da
Application granted granted Critical
Publication of DK2528602T4 publication Critical patent/DK2528602T4/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/186—Quaternary ammonium compounds, e.g. benzalkonium chloride or cetrimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Materials For Medical Uses (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DK11737745.7T 2010-01-28 2011-01-28 Formuleringer af bendamustin DK2528602T4 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US29910010P 2010-01-28 2010-01-28
PCT/US2011/022958 WO2011094565A1 (en) 2010-01-28 2011-01-28 Formulations of bendamustine

Publications (2)

Publication Number Publication Date
DK2528602T3 DK2528602T3 (da) 2017-01-23
DK2528602T4 true DK2528602T4 (da) 2020-04-27

Family

ID=44309429

Family Applications (2)

Application Number Title Priority Date Filing Date
DK16020363.4T DK3158991T3 (da) 2010-01-28 2011-01-28 Formuleringer af bendamustin
DK11737745.7T DK2528602T4 (da) 2010-01-28 2011-01-28 Formuleringer af bendamustin

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DK16020363.4T DK3158991T3 (da) 2010-01-28 2011-01-28 Formuleringer af bendamustin

Country Status (16)

Country Link
US (17) US8609707B2 (da)
EP (3) EP3158991B1 (da)
JP (2) JP5795600B2 (da)
CA (1) CA2787568C (da)
CY (2) CY1118769T1 (da)
DK (2) DK3158991T3 (da)
ES (2) ES2609106T5 (da)
HR (2) HRP20161771T4 (da)
HU (2) HUE031208T2 (da)
LT (2) LT3158991T (da)
PL (2) PL3158991T3 (da)
PT (2) PT3158991T (da)
RS (2) RS62327B1 (da)
SI (2) SI3158991T1 (da)
SM (3) SMT201700043T1 (da)
WO (1) WO2011094565A1 (da)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SMT201700043T1 (it) 2010-01-28 2017-03-08 Eagle Pharmaceuticals Inc Formulazioni di bendamustina
MX363465B (es) 2011-02-18 2019-03-25 Kythera Biopharmaceuticals Inc Tratamiento de la grasa submental.
EP2806872A4 (en) * 2012-01-24 2014-12-03 Innopharma Inc BENDAMUSTIN COMPOSITIONS AND RELATED METHODS
JP2015506989A (ja) * 2012-02-14 2015-03-05 イーグル・ファーマシューティカルズ・インコーポレーテッド ベンダムスチン製剤
JP6250628B2 (ja) * 2012-03-20 2017-12-20 イーグル・ファーマシューティカルズ・インコーポレーテッド ベンダムスチンの製剤
CN104271135B (zh) * 2012-03-20 2017-05-17 赛多斯有限责任公司 在要求减少施用容量的患者中治疗苯达莫司汀响应性状况的方法
EP3043648B1 (en) 2013-08-27 2023-09-20 Vasilios VOUDOURIS Bendamustine pharmaceutical compositions
KR20160060656A (ko) * 2013-09-20 2016-05-30 산텐 세이야꾸 가부시키가이샤 폴리에틸렌글리콜 함유 조성물
US20160235717A1 (en) * 2013-10-11 2016-08-18 Luitpold Pharmaceuticals, Inc. Bendamustine pharmaceutical compositions
EP3116481A1 (en) * 2014-03-13 2017-01-18 Vasilios VOUDOURIS Bendamustine solid dispersions and continuous infusion
WO2016005995A2 (en) * 2014-07-10 2016-01-14 Leiutis Pharmaceuticals Pvt. Ltd. Glycol free stable liquid compositions of bendamustine
US9603930B2 (en) 2014-12-04 2017-03-28 Navinta, Llc Liquid bendamustine formulation
JP2018532806A (ja) * 2015-11-04 2018-11-08 キセラ バイオファーマシューティカルズ インコーポレイテッド デオキシコール酸およびその塩による蓄積脂肪の処置方法
US10905677B2 (en) 2016-08-31 2021-02-02 Navinta, Llc Bendamustine solution formulations
US11826466B2 (en) 2016-08-31 2023-11-28 Navinta, Llc Bendamustine solution formulations
EP3773498B1 (en) 2018-03-29 2022-06-22 Project Pharmaceutics GmbH Liquid pharmaceutical formulation
EP3836921B1 (en) 2018-08-17 2025-10-08 Hospira Australia Pty Ltd Liquid bendamustine pharmaceutical compositions
US11730815B2 (en) 2018-11-26 2023-08-22 Good Health, Llc Stable liquid pharmaceutical compositions comprising bendamustine
JP2020090481A (ja) * 2018-11-27 2020-06-11 日本化薬株式会社 ベンダムスチンを含有する溶液製剤
JP7235288B2 (ja) * 2019-01-07 2023-03-08 コーアイセイ株式会社 ベンダムスチンの液体製剤
WO2020170104A1 (en) * 2019-02-18 2020-08-27 Shilpa Medicare Limited Liquid bendamustine parenteral compositions
WO2021161876A1 (ja) * 2020-02-10 2021-08-19 富士フイルム株式会社 ベンダムスチン液剤
JP2023529033A (ja) * 2020-04-09 2023-07-07 ビカ・バイオテック（グアンジョウ）・カンパニー・リミテッド ベンダムスチン組成物及びその用途
JP2024537431A (ja) 2021-10-22 2024-10-10 プロジェクト ファーマシューティクス ゲーエムベーハー 液状薬学的製剤
GB202118175D0 (en) 2021-12-15 2022-01-26 Arecor Ltd Novel composition
US11707450B1 (en) * 2022-03-03 2023-07-25 Slayback Pharma Llc Stable pharmaceutical compositions of bendamustine

Family Cites Families (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE80967C (da)
DE159289C (da) * 1903-10-08 1905-03-16
DE152989C (da)
US4071620A (en) 1977-01-10 1978-01-31 American Home Products Corporation Stabilization of oxygen sensitive dose forms
DD152989A1 (de) 1980-09-11 1981-12-16 Klaus Kunze Anordnung zur korrektur von soll-und istwerten
DD159289A1 (de) * 1981-06-01 1983-03-02 Uwe Olthoff Verfahren zur herstellung stabiler injektionsloesungen von n-lostverbindungen
DE3446873A1 (de) * 1984-12-21 1986-07-10 Merckle Gmbh Fluessige diclofenac-zubereitungen
US5204335A (en) 1986-10-31 1993-04-20 Asta Pharma Aktiengesellschaft Ifosfamide lyophilisate and process for its preparation
US4879286A (en) 1987-01-28 1989-11-07 Lyphomed, Inc. Cyclophosphamide
US5223515A (en) 1988-08-18 1993-06-29 Takeda Chemical Industries, Ltd. Injectable solution containing a pyridyl methylsulfinylbenzimidazole
DK0725642T3 (da) 1993-10-27 2000-05-29 Upjohn Co Stabiliseret prostaglandin E1
MX9602955A (es) 1994-01-24 1997-06-28 Procter & Gamble Procedimiento para solubizar activos farmaceuticos dificilmente solubles.
US6261537B1 (en) 1996-10-28 2001-07-17 Nycomed Imaging As Diagnostic/therapeutic agents having microbubbles coupled to one or more vectors
WO1999001118A2 (en) 1997-07-01 1999-01-14 Atherogenics, Inc. Antioxidant enhancement of therapy for hyperproliferative conditions
WO1999053918A1 (en) * 1998-04-20 1999-10-28 Eisai Co., Ltd. Stabilized compositions containing benzimidazole-type compounds
US6569402B1 (en) 1998-12-18 2003-05-27 Bristol-Myers Squibb Pharma Company Vitronectin receptor antagonist pharmaceuticals
US6686365B2 (en) * 2000-02-04 2004-02-03 Eli Lilly And Company Pharmaceutical composition
US6989139B2 (en) 2000-02-15 2006-01-24 Bristol-Myers Squibb Pharma Company Matrix metalloproteinase inhibitors
JP2005538030A (ja) 2000-06-21 2005-12-15 デュポン ファーマシューティカルズ カンパニー 組み合わせ療法での使用のための血管新生障害の画像診断用医薬
AU2001271435A1 (en) 2000-06-21 2002-01-02 Bristol-Myers Squibb Pharma Company Vitronectin receptor antagonist pharmaceuticals
CA2413957A1 (en) 2000-06-21 2001-12-27 Bristol-Myers Squibb Pharma Company Vitronectin receptor antagonist pharmaceuticals for use in combination therapy
AUPQ849900A0 (en) 2000-06-30 2000-07-27 Dbl Australia Pty Ltd. Injectable composition
CA2413538A1 (en) 2000-07-06 2002-01-17 Bristol-Myers Squibb Pharma Company Stable radiopharmaceutical compositions and methods for preparation thereof
WO2002032427A1 (en) * 2000-10-20 2002-04-25 Galephar M/F Stable oral formulation containing benzimidazole derivative
US7252799B2 (en) * 2001-08-31 2007-08-07 Clearant, Inc. Methods for sterilizing preparations containing albumin
AR040693A1 (es) * 2002-07-30 2005-04-13 Wyeth Corp Formulaciones parenterales
US20060035945A1 (en) 2003-05-30 2006-02-16 Giorgio Attardo Triheterocyclic compounds, compositions, and methods for treating cancer or viral diseases
US20060001597A1 (en) 2004-06-30 2006-01-05 Sokbom Han Image processing apparatus, systems and associated methods
MX2007005361A (es) 2004-11-05 2008-01-11 Cephalon Inc Tratamientos para cancer.
PT1814517E (pt) 2004-11-22 2010-11-03 Venus Remedies Ltd Formulação parentérica líquida não aquosa de aceclofenac
US8436190B2 (en) 2005-01-14 2013-05-07 Cephalon, Inc. Bendamustine pharmaceutical compositions
US7872050B2 (en) 2005-03-14 2011-01-18 Yaupon Therapeutics Inc. Stabilized compositions of volatile alkylating agents and methods of using thereof
US20080200383A1 (en) 2005-04-08 2008-08-21 Amylin Pharmaceuticals, Inc. Pharmaceutical Formulations Comprising Incretin Peptide and Aprotic Polar Solvent
US8158152B2 (en) 2005-11-18 2012-04-17 Scidose Llc Lyophilization process and products obtained thereby
CN1850048A (zh) 2006-06-09 2006-10-25 山东蓝金生物工程有限公司 一种含血管抑制剂的抗癌缓释注射剂
WO2008020584A1 (en) 2006-08-14 2008-02-21 Eisai R & D Management Co., Ltd. Stable lyophilized preparation
EP2073802A1 (en) 2006-10-12 2009-07-01 Astex Therapeutics Limited Pharmaceutical combinations
US8414909B2 (en) 2006-11-20 2013-04-09 Lutonix, Inc. Drug releasing coatings for medical devices
DE102007003184A1 (de) 2007-01-22 2008-07-24 Orlowski, Michael, Dr. Verfahren zur Beladung von strukturierten Oberflächen
US20090082416A1 (en) 2007-09-25 2009-03-26 Protia, Llc Deuterium-enriched bendamustine
AR072777A1 (es) 2008-03-26 2010-09-22 Cephalon Inc Formas solidas de clorhidrato de bendamustina
CA2735899A1 (en) 2008-09-25 2010-04-01 Cephalon, Inc. Liquid formulations of bendamustine
US8076366B2 (en) 2009-01-15 2011-12-13 Cephalon, Inc. Forms of bendamustine free base
ES2525257T3 (es) 2009-02-25 2014-12-19 Supratek Pharma, Inc. Composiciones de ciclopolisacárido y de bendamustina
WO2010114770A1 (en) 2009-03-30 2010-10-07 Cerulean Pharma Inc. Polymer-agent conjugates, particles, compositions, and related methods of use
US20100273730A1 (en) 2009-04-27 2010-10-28 Innopharmax, Inc. Self-emulsifying pharmaceutical compositions of hydrophilic drugs and preparation thereof
JP2012525387A (ja) * 2009-04-28 2012-10-22 セファロン、インク． ベンダムスチンの経口製剤
CN101584668A (zh) 2009-06-19 2009-11-25 江苏奥赛康药业有限公司 盐酸苯达莫司汀冻干粉针剂
WO2010148288A2 (en) 2009-06-19 2010-12-23 Lyotropic Therapeutics, Inc. Pharmaceutical formulations with low aqueous levels of free unbound drug
US20110015245A1 (en) 2009-07-20 2011-01-20 Valery Alakhov Bendamustine amphiphilic cationic compositions
US8389558B2 (en) 2009-07-20 2013-03-05 Supratek Pharma Inc. Bendamustine amphiphilic anionic compositions
US7772274B1 (en) * 2009-10-19 2010-08-10 Scidose, Llc Docetaxel formulations with lipoic acid
SMT201700043T1 (it) 2010-01-28 2017-03-08 Eagle Pharmaceuticals Inc Formulazioni di bendamustina
WO2011103150A2 (en) 2010-02-18 2011-08-25 Cephalon, Inc. Lyophilized preparations of bendamustine
CA2799579A1 (en) 2010-05-21 2011-11-24 Intellikine, Inc. Chemical compounds, compositions and methods for kinase modulation
JP2013540104A (ja) 2010-07-28 2013-10-31 イーグル・ファーマシューティカルズ・インコーポレーテッド 延長された保存安定性を有するペメトレキセドを含有する医薬組成物
EP2635558A4 (en) 2010-11-01 2014-08-06 Shilpa Medicare Ltd PROCESS FOR PREPARING BENDAMUSTINE HYDROCHLORIDE MONOHYDRATE
JP2014516075A (ja) 2011-06-06 2014-07-07 シェブロン フィリップス ケミカル カンパニー エルピー 癌治療のためのメタロセン化合物の使用
CA2857177C (en) 2011-12-05 2020-06-23 Bio-Rad Laboratories, Inc. Recombinant deamidated gliadin antigen
AU2012347972B2 (en) 2011-12-05 2018-05-10 X-Body, Inc. PDGF receptor beta binding polypeptides
EP2806872A4 (en) 2012-01-24 2014-12-03 Innopharma Inc BENDAMUSTIN COMPOSITIONS AND RELATED METHODS
JP2015506989A (ja) 2012-02-14 2015-03-05 イーグル・ファーマシューティカルズ・インコーポレーテッド ベンダムスチン製剤
JP6250628B2 (ja) 2012-03-20 2017-12-20 イーグル・ファーマシューティカルズ・インコーポレーテッド ベンダムスチンの製剤
CN104271135B (zh) 2012-03-20 2017-05-17 赛多斯有限责任公司 在要求减少施用容量的患者中治疗苯达莫司汀响应性状况的方法
JP6331468B2 (ja) 2014-02-27 2018-05-30 住友ベークライト株式会社 金属ラミネート用フィルム、ラミネート金属板および金属容器
US11707450B1 (en) * 2022-03-03 2023-07-25 Slayback Pharma Llc Stable pharmaceutical compositions of bendamustine

Also Published As

Publication number Publication date
US20180296536A1 (en) 2018-10-18
US20180000789A1 (en) 2018-01-04
EP2528602B2 (en) 2020-02-12
HRP20210915T1 (hr) 2021-10-01
PT3158991T (pt) 2021-06-23
US20250186402A1 (en) 2025-06-12
SI2528602T2 (sl) 2020-10-30
US11844783B2 (en) 2023-12-19
CA2787568C (en) 2019-04-02
HRP20161771T4 (hr) 2020-08-07
US10010533B2 (en) 2018-07-03
CA2787568A1 (en) 2011-08-04
JP2013518130A (ja) 2013-05-20
US20190350904A1 (en) 2019-11-21
US12138248B2 (en) 2024-11-12
JP2016020365A (ja) 2016-02-04
US20160143888A1 (en) 2016-05-26
PT2528602T (pt) 2017-01-12
US20240293372A1 (en) 2024-09-05
SMT202100348T1 (it) 2021-07-12
US20160143887A1 (en) 2016-05-26
US20230115693A1 (en) 2023-04-13
DK2528602T3 (da) 2017-01-23
US12350257B2 (en) 2025-07-08
DK3158991T3 (da) 2021-06-14
US20240293373A1 (en) 2024-09-05
SMT201700043B (it) 2017-03-08
CY1124262T1 (el) 2022-07-22
WO2011094565A1 (en) 2011-08-04
CY1118769T1 (el) 2017-07-12
ES2609106T3 (es) 2017-04-18
HRP20161771T1 (hr) 2017-02-24
HUE054836T2 (hu) 2021-10-28
ES2609106T5 (es) 2020-11-10
US20180296535A1 (en) 2018-10-18
US20250177356A1 (en) 2025-06-05
SI2528602T1 (sl) 2017-03-31
US20140024691A1 (en) 2014-01-23
US8609707B2 (en) 2013-12-17
SI3158991T1 (sl) 2021-10-29
HUE031208T2 (hu) 2017-07-28
LT3158991T (lt) 2021-07-12
JP5795600B2 (ja) 2015-10-14
US9265831B2 (en) 2016-02-23
US20210393594A1 (en) 2021-12-23
PL3158991T3 (pl) 2021-09-27
EP3895694A1 (en) 2021-10-20
EP3158991B1 (en) 2021-03-17
US11103483B2 (en) 2021-08-31
US9572797B2 (en) 2017-02-21
EP2528602A4 (en) 2014-01-22
EP3158991A1 (en) 2017-04-26
EP2528602A1 (en) 2012-12-05
JP6133943B2 (ja) 2017-05-24
PL2528602T5 (pl) 2020-09-07
US20240075013A1 (en) 2024-03-07
US20110184036A1 (en) 2011-07-28
RS62327B1 (sr) 2021-10-29
US9572796B2 (en) 2017-02-21
EP2528602B1 (en) 2016-10-05
US20250295637A1 (en) 2025-09-25
US12343333B2 (en) 2025-07-01
US20230115164A1 (en) 2023-04-13
ES2875374T3 (es) 2021-11-10
PL2528602T3 (pl) 2017-03-31
LT2528602T (lt) 2017-02-27
US11872214B2 (en) 2024-01-16
SMT201700043T1 (it) 2017-03-08
RS55491B2 (sr) 2020-11-30
RS55491B1 (sr) 2017-04-28

Similar Documents

Publication Publication Date Title
DK2528602T4 (da) Formuleringer af bendamustin
HUS1900001I1 (hu) Transztiretin expressziójának módosítása
DK3725778T4 (da) Formuleringer af enzalutamid
DK2498756T3 (da) Tabletformuleringer af neratinibmaleat
DK2567524T3 (da) Reduktion af protokolspild
DK3156056T3 (da) Farmaceutiske sammensætninger der består af sorbitanestere
EP2736491A4 (en) BEPOTASTIN COMPOSITION
DK2603232T3 (da) Stabile formuleringer af linaclotid
EP2675909A4 (en) GLUCOSYLSTEVIA COMPOSITION
EP2720561A4 (en) Stevia-COMPOSITION
DK3235812T3 (da) Deutererede derivater af ivacaftor
LT3222272T (lt) Farmacinė karbetocino kompozicija
EP2713762A4 (en) Stevia-COMPOSITION
IL223725B (en) Formulations of rifaximin and uses thereof
DK2633006T3 (da) Fremstilling af fornybart bio-destillat
DK2827862T3 (da) Formuleringer af bendamustin
DK3831406T3 (da) Stabile formuleringer af Neisseria-Meningitidis-RLP2086-antigener
DK2822568T3 (da) Anvendelser af caseinsammensætninger
DK3106150T3 (da) Forbedrede farmaceutiske sammensætninger af pimobendan
EP2552212A4 (en) IMPROVED FORMULATION
DK2800572T3 (da) Sammensætning af ellagitannin-rige ekstrakter
PT2402012E (pt) Formulações líquidas de fumarato de rupatadina
DK2648696T3 (da) Ny indgivelsesform af racecadotril
DK2925338T3 (da) Frysetørret formulering af tat-nr2b9c
SMT201600380B (it) Formulazioni di darunavir